MedTrace Logo

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

NCT04801017 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2021-03-16

No results posted yet for this study

Summary

Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.

Conditions

Interventions

DRUG

OT-101

TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide

DRUG

Artemisinin

Herbal Supplement/ Purified extract from Artemisia

DRUG

Placebo

0.9% sodium chloride injection

Sponsors & Collaborators

  • Oncotelic Inc.

    lead INDUSTRY

Principal Investigators

  • Vuong Trieu, PhD · Oncotelic Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-08-31
Completion
2021-10-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04801017 on ClinicalTrials.gov